

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): March 13, 2018**

---

**IMMUNOCELLULAR THERAPEUTICS, LTD.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation or organization)

**001-35560**  
(Commission  
File Number)

**93-1301885**  
(I.R.S. Employer  
Identification No.)

**30721 Russell Ranch Road, Suite 140**  
**Westlake Village, California 91362**  
(Address of Principal Executive Offices) (Zip Code)

**Registrant's telephone number, including area code: (818) 264-2300**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 2.02. Results of Operations and Financial Condition.**

On March 13, 2018, ImmunoCellular Therapeutics, Ltd. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2017. A copy of this press release is attached as Exhibit 99.1.

This information, including exhibits attached hereto and the information under item 9.01 below, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

Exhibit	Description
99.1	<a href="#">Press Release, dated March 13, 2018</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 13, 2018

IMMUNOCELLULAR THERAPEUTICS, LTD.

By: /s/ David Fractor

David Fractor  
Principal Accounting Officer



## **ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results**

*-Continued Progress in Stem-to-T-Cell Program-  
-Strengthened Financial Condition-  
-Conference Call Today at 5:00 pm ET-*

Los Angeles, CA – March 13, 2018 – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE American: IMUC) today announced financial results for the fourth quarter and full year ended December 31, 2017.

Anthony J. Gringeri, PhD, President and Chief Executive Officer commented: “We ended 2017 in a strong financial condition with approximately \$6.6 million in cash and \$4.6 million in both working capital and stockholders’ equity. During the fourth quarter of 2017 we received approximately \$5.6 million of net proceeds from exercises of warrants issued in our July 2017 underwritten public offering, and we implemented payment programs with our key vendors, both of which contributed to a strengthening of our balance sheet. In the second half of 2017, we also reduced our expenses, and are operating in what we believe is a capital-efficient manner, which should meaningfully extend our cash runway. We believe that with our current financial plan, we may successfully be able to regain compliance with the NYSE American listing standards regarding stockholders’ equity.”

Dr. Gringeri continued: “In the fourth quarter of 2017, we achieved a key milestone in our Stem-to-T-Cell research program by successfully packaging T cell receptor DNA into a viral vector and transferring that DNA into human hematopoietic stem cells. We are currently working to achieve our next milestone in this program, optimizing transfection conditions for the hematopoietic stem cells, which would then enable preclinical testing. Additionally, we are completing the wind-down of ICT-107 activities while continuing to seek partnership opportunities for our clinical-stage anticancer assets. In addition, as previously announced, we recently retained Ladenburg Thalmann & Co. Inc. as our strategic financial advisor to assist in the review of our business and assets and the exploration of strategic opportunities for enhancing stockholder value, including the potential sale or merger of the Company. It is important to remember that we cannot guarantee that this process will culminate in a transaction. Nevertheless, it is a top priority for our management and board, and we are optimistic that this next phase can identify further opportunities for creating value for ImmunoCellular stockholders.”

Fourth Quarter and Full Year 2017 Financial Results

---

For the year ended December 31, 2017, the Company incurred a net loss of \$14.3 million compared to \$22.1 million in 2016. The net loss available to common stockholders for the year ended December 31, 2017, was \$17.7 million, or \$1.23 per basic and diluted common share, compared to \$22.1 million, or \$7.89 per basic and diluted common share, in 2016. The 2017 net loss available to common stockholders includes the net loss of \$14.3 million, plus \$2.3 million of deemed dividends and \$1.0 million of original issue discount associated with the convertible preferred stock issued as part of the July 2017 financing. There were no similar charges during 2016.

The decrease in net loss between years is due to reductions in both research and development expenses and general and administrative expenses. Research and development expenses in 2017 decreased to \$17.1 million from \$19.1 million in the prior year. The decrease reflects the suspension of the phase 3 trial of ICT-107 in June 2017. In 2017, general and administrative expenses were \$4.0 million compared to \$5.0 million in 2016. Simultaneous with the suspension of the ICT -107 trial, the Company reduced the number of administrative personnel, downsized its office space and reduced other expenses. These reductions were partially offset by higher professional fees. Additionally, during 2017, the Company recognized a gain of \$7.7 million related to the de-recognition of the liability resulting from advances, plus accrued interest, from the California Institute of Regenerative Medicine. In 2016, the Company recognized a gain of \$3.8 million related to the revaluation of its warrant derivatives. During 2017, the Company early adopted ASU 2017-11, which allowed the Company to reclassify its warrant derivatives as equity. Accordingly, there were no gains or losses associated with warrant revaluation during 2017.

Net loss for the quarter ended December 31, 2017, was \$431,000, or \$0.01 per basic and diluted common share, compared to \$6.3 million, or \$1.36 per basic and diluted common share, for the quarter ended December 31, 2016. The decrease in the net loss is attributable to reduction in research and development associated with the suspension of the phase 3 trial of ICT-107 as well as certain discounts that the Company negotiated with key vendors.

In July 2017, ImmunoCellular completed an underwritten public offering that provided \$4.0 million in net proceeds from the sale of convertible preferred stock, with the potential to secure an additional \$9 million in funding over the 12 months following the closing of the financing from the exercise of warrants to purchase preferred stock issued in the financing transaction. As part of the financing, the Company issued three warrant tranches of \$3 million each with maturities in October 2017, January 2018 and July 2018. Through December 31, 2017, the Company received \$7.8 million in net proceeds from the exercise of warrants. The Company is using the financing proceeds to move forward with a restructuring plan focused on winding down ICT-107 activities and advancing early-stage research programs while continuing to seek partnership opportunities for development-stage assets. As of December 31, 2017, the Company had \$6.6 million in cash, \$4.6 million of working capital and stockholders' equity and 41,913,256 shares of common stock outstanding.

[Conference Call and Webcast Today](#)

---

ImmunoCellular plans to hold a conference call and webcast today, March 13, 2018, at 5:00 pm ET to review 2017 financial results and provide a business update. The call will be hosted by Anthony J. Gringeri, PhD, President and Chief Executive Officer.

LIVE CALL: (877) 853-5636 (toll-free); international dial-in: (631) 291-4544; conference code 4075529.

WEBCAST: Interested parties who wish to listen to the webcast should visit the Investor Relations section of ImmunoCellular's website at [www.imuc.com](http://www.imuc.com), under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event.

The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

#### About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140, which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors. To learn more about ImmunoCellular, please visit [www.imuc.com](http://www.imuc.com).

#### Forward-Looking Statements for ImmunoCellular Therapeutics

This press release contains certain forward-looking statements, including statements regarding ImmunoCellular's intentions and current expectations concerning, among other things, whether ImmunoCellular will be able to finance its ongoing operations following termination of existing clinical development programs, reduce outstanding obligations to creditors of the Company and minimize or defer the costs of restructuring in order to enable its immunotherapy program; whether ImmunoCellular will be able to identify and execute a successful strategic transaction; the likelihood, timing and outcome of ImmunoCellular's possible strategic alternatives, including a partnership, collaboration or restructuring; ImmunoCellular's beliefs regarding the advantages and therapeutic and commercial value of its programs; ImmunoCellular's ability to maintain its listing on the NYSE American and regain compliance with the NYSE American's listing standards; ImmunoCellular's ability to advance its Stem-to-T-Cell program and achieve certain milestones; and ImmunoCellular's ability to achieve its other clinical, operational, strategic and financial goals. Forward-looking statements are not guarantees of future performance and are subject to a number of risks and uncertainties, including the availability of resources to continue to develop ImmunoCellular's product candidates and the uncertain timing of completion and success of clinical trials. Additional risks and uncertainties are described under the heading "Risk Factors" in ImmunoCellular's most recently filed quarterly report on Form 10-Q for the period ended September 30, 2017 and subsequent filings with the Securities and Exchange Commission.

---

Except as required by law, ImmunoCellular undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact :

ImmunoCellular Therapeutics, Ltd.

Jane Green

(267) 457-3734 direct

(415) 652-4819 mobile

[jane@jmgcomm.com](mailto:jane@jmgcomm.com)

Lytham Partners, LLC

Joe Dorame, Robert Blum, or Joseph Diaz

(602) 889-9700

[imuc@lythampartners.com](mailto:imuc@lythampartners.com)

Consolidated Balance Sheets

	<u>12/31/2017</u>	<u>12/31/2016</u>
Cash	\$ 6,629,870	\$ 11,437,118
Other current assets	378,787	1,977,671
Non current assets	568	3,475,201
Total assets	<u>\$ 7,009,225</u>	<u>\$ 16,889,990</u>
Current liabilities	\$ 2,360,754	\$ 3,238,943
Warrant liability	-	573,560
CIRM liability	-	6,945,741
Shareholders' equity	4,648,471	6,131,746
	<u>\$ 7,009,225</u>	<u>\$ 16,889,990</u>

---

---

Consolidated Statement of Operations

	Year ended 12/31/17	Year ended 12/31/16	Year ended 12/31/15
Revenue	\$ —	\$ —	\$ —
Research and development	17,126,244	19,105,727	10,896,591
General and administrative	4,027,200	5,006,398	4,616,500
Loss before other income (expenses)	(21,153,444)	(24,112,125)	(15,513,091)
Interest income	4,680	24,381	19,863
Interest expense	(882,683)	(1,311,836)	(133,905)
Financing expense	—	(498,520)	(88,939)
Change in fair value of warrant liability	—	3,812,398	2,925,258
Derecognition of CIRM liability	7,719,440	—	—
Net loss before provision for income taxes	(14,312,007)	(22,085,702)	(12,790,814)
Deemed dividend on convertible preferred stock	(2,284,396)	—	—
Accretion of original issue discount on preferred stock	(1,033,470)	—	—
Preferred stock dividends	(10,024)	—	—
Deemed dividend from warrant repricing	(41,756)	—	—
Net loss attributable to common shareholders	<u>\$ (17,681,653)</u>	<u>\$ (22,085,702)</u>	<u>\$ (12,790,814)</u>
Net loss attributable per share to common stockholder, basic and diluted:	<u>\$ (1.23)</u>	<u>\$ (7.89)</u>	<u>\$ (5.87)</u>

---